UVI3003 is a RXR antagonist. It displays high RXR binding affinity. UVI3003 does not affect the corepressor interaction capacity of the RARα subunit within the context of the RAR-RXR heterodimer.
For research use only. We do not sell to patients.
| Name | UVI3003 |
|---|---|
| Iupac Chemical Name | (2E)-3-{4-hydroxy-3-[5,5,8,8-tetramethyl-3-(pentyloxy)-5,6,7,8-tetrahydronaphthalen-2-yl]phenyl}prop-2-enoic acid |
| Synonyms | UVI3003, UVI 3003, UVI-3003 |
| Molecular Formula | C28H36O4 |
| Molecular Weight | 436.59 |
| Smile | O=C(O)/C=C/C1=CC=C(O)C(C2=C(OCCCCC)C=C3C(C)(C)CCC(C)(C)C3=C2)=C1 |
| InChiKey | APJSHECCIRQQDV-ZRDIBKRKSA-N |
| InChi | InChI=1S/C28H36O4/c1-6-7-8-15-32-25-18-23-22(27(2,3)13-14-28(23,4)5)17-21(25)20-16-19(9-11-24(20)29)10-12-26(30)31/h9-12,16-18,29H,6-8,13-15H2,1-5H3,(H,30,31)/b12-10+ |
| CAS Number | 847239-17-2 |
| Related CAS |
| Packaging | Price | Availability | Purity | Shipping Time |
|---|---|---|---|---|
| Bulk | Enquiry | Enquiry | Enquiry |
| Formulation | Off-white solid to white solid |
|---|---|
| Purity | >98% |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| Solubility | Soluble in DMSO |
| Handling | |
| Shipping Condition | Shipped under ambient temperature |
| HS Code |
| Targets | |
|---|---|
| Mechanism | |
| Cell study | |
| Animal study | |
| Clinical study |